% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kostareli:128951,
author = {E. Kostareli and T. Hielscher$^*$ and M. Zucknick and L.
Baboci$^*$ and G. Wichmann and D. Holzinger$^*$ and O.
Mücke and M. Pawlita$^*$ and A. Del Mistro and P.
Boscolo-Rizzo and M. C. Da Mosto and G. Tirelli and P.
Plinkert and A. Dietz and C. Plass$^*$ and D. Weichenhan$^*$
and J. Hess$^*$},
title = {{G}ene promoter methylation signature predicts survival of
head and neck squamous cell carcinoma patients.},
journal = {Epigenetics},
volume = {11},
number = {1},
issn = {1559-2308},
address = {Austin, Tex.},
publisher = {Landes Bioscience},
reportid = {DKFZ-2017-04963},
pages = {61 - 73},
year = {2016},
abstract = {Infection with high-risk types of human papilloma virus
(HPV) is currently the best-established prognostic marker
for head and neck squamous cell carcinoma (HNSCC), one of
the most common and lethal human malignancies worldwide.
Clinical trials have been launched to address the concept of
treatment de-escalation for HPV-positive HNSCC with the
final aim to reduce treatment related toxicity and
debilitating long-term impacts on the quality of life.
However, HPV-related tumors are mainly restricted to
oropharyngeal SCC (OPSCC) and there is an urgent need to
establish reliable biomarkers for all patients at high risk
for treatment failure. A patient cohort (n = 295) with
mainly non-OPSCC $(72.9\%)$ and a low prevalence of
HPV16-related tumors $(8.8\%)$ was analyzed by MassARRAY to
determine a previously established prognostic methylation
score (MS). Kaplan-Meier revealed a highly significant
correlation between a high MS and a favorable survival for
OPSCC (P = 0.0004) and for non-OPSCC (P<0.0001), which was
confirmed for all HNSCC by multivariate Cox regression
models (HR: 9.67, $95\%$ CI [4.61-20.30], P<0.0001). Next,
we established a minimal methylation signature score (MMSS),
which consists of ten most informative of the originally 62
CpG units used for the MS. The prognostic value of the MMSS
was confirmed by Kaplan-Meier analysis for all HNSCC
(P<0.0001) and non-OPSCC (P = 0.0002), and was supported by
multivariate Cox regression models for all HNSCC (HR: 2.15,
$95\%$ CI [1.36-3.41], P = 0.001). In summary, the MS and
the MMSS exhibit an excellent performance as prognosticators
for survival, which is not limited by the anatomical site,
and both could be implemented in future clinical trials.},
keywords = {Biomarkers, Tumor (NLM Chemicals)},
cin = {F020 / C010 / G405 / C060},
ddc = {610},
cid = {I:(DE-He78)F020-20160331 / I:(DE-He78)C010-20160331 /
I:(DE-He78)G405-20160331 / I:(DE-He78)C060-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:26786582},
pmc = {pmc:PMC4846111},
doi = {10.1080/15592294.2015.1137414},
url = {https://inrepo02.dkfz.de/record/128951},
}